| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Characteristics of major outer membrane proteins of Haemophilus influenzae.
|
J Bacteriol
|
1983
|
2.66
|
|
2
|
Homogeneity of cell envelope protein subtypes, lipopolysaccharide serotypes, and biotypes among Haemophilus influenzae type b from patients with meningitis in The Netherlands.
|
J Infect Dis
|
1983
|
2.51
|
|
3
|
Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.
|
Vaccine
|
2006
|
1.67
|
|
4
|
Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.
|
Infect Immun
|
1996
|
1.54
|
|
5
|
Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.
|
Vaccine
|
1999
|
1.46
|
|
6
|
Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine.
|
Vaccine
|
1996
|
1.27
|
|
7
|
Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines.
|
Vaccine
|
1999
|
1.24
|
|
8
|
A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.
|
Vaccine
|
2009
|
1.09
|
|
9
|
Humoral immune responses to Neisseria meningitidis in children.
|
Infect Immun
|
1999
|
1.08
|
|
10
|
Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine.
|
Infect Immun
|
1997
|
1.02
|
|
11
|
Cellular immune responses to Neisseria meningitidis in children.
|
Infect Immun
|
1999
|
0.97
|
|
12
|
Cimetidine vs gastroscopy.
|
Med J Aust
|
1985
|
0.96
|
|
13
|
Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption.
|
Clin Vaccine Immunol
|
2011
|
0.93
|
|
14
|
Sero- and subtypes of group B meningococci causing invasive infections in Finland in 1976-87.
|
Scand J Infect Dis
|
1989
|
0.89
|
|
15
|
Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly.
|
Vaccine
|
2006
|
0.87
|
|
16
|
Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys.
|
Vaccine
|
2000
|
0.86
|
|
17
|
The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
|
Int J Infect Dis
|
2007
|
0.84
|
|
18
|
Serological study of meningococcal isolates in Switzerland and France 1980-1986.
|
Eur J Clin Microbiol Infect Dis
|
1988
|
0.81
|
|
19
|
Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection.
|
Vaccine
|
2002
|
0.77
|
|
20
|
European Commission COST/STD Initiative. Report of the expert panel VIII. New vaccines, especially new combined vaccines.
|
Vaccine
|
1996
|
0.76
|
|
21
|
Microheterogeneity in the recognition of a HLA-DR2-restricted T cell epitope from a meningococcal outer membrane protein.
|
Eur J Immunol
|
1993
|
0.76
|
|
22
|
Development and efficacy assessment of combination vaccines, with emphasis on acellular pertussis.
|
Dev Biol Stand
|
1998
|
0.75
|
|
23
|
Preclinical and clinical development of new vaccines.
|
Biologicals
|
1998
|
0.75
|